Literature DB >> 3308082

Continuous-infusion cisplatin and bolus 5-fluorouracil in colorectal carcinoma.

M R Posner1, J F Belliveau, A B Weitberg, K Sabbath, M C Wiemann, F J Cummings, P Calabresi.   

Abstract

Twenty-one evaluable patients with metastatic colorectal carcinoma were treated with a combination of continuous-infusion cisplatin (25 mg/m2/day X 3 days) and bolus 5-fluorouracil (400 mg/m2/day X 3 days). Toxicity was minimal. Seven patients (33%) responded. All responses were observed among the 16 previously untreated patients (44%) and lasted a median of 30 weeks. The results indicate the need for phase III trials of this treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3308082

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  2 in total

1.  Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-fluorouracil.

Authors:  J F Belliveau; M R Posner; G W Crabtree; A B Weitberg; M C Wiemann; F J Cummings; G P O'Leary; E Ingersoll; P Calabresi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.

Authors:  A S Planting; M E van der Burg; M J van den Bent; M de Boer-Dennert; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.